• Home
  • Search Results
  • Randomized clinical trial of goal-directed fluid therapy within an enhanced recovery protocol for elective colectomy.

Randomized clinical trial of goal-directed fluid therapy within an enhanced recovery protocol for elective colectomy.

The British journal of surgery (2012-11-08)
S Srinivasa, M H G Taylor, P P Singh, T-C Yu, M Soop, A G Hill

Goal-directed fluid therapy (GDFT) has been compared with liberal fluid administration in non-optimized perioperative settings. It is not known whether GDFT is of value within an enhanced recovery protocol incorporating fluid restriction. This study evaluated GDFT under these circumstances in patients undergoing elective colectomy. Patients undergoing elective laparoscopic or open colectomy within an established enhanced recovery protocol (including fluid restriction) were randomized to GDFT or no GDFT. Bowel preparation was permitted for left colonic operations at the surgeon's discretion. Exclusion criteria included rectal tumours and stoma formation. The primary outcome was a patient-reported surgical recovery score (SRS). Secondary endpoints included clinical outcomes and physiological measures of recovery. Eighty-five patients were randomized, and there were 37 patients in each group for analysis. Nine patients in the GDFT and four in the fluid restriction group received oral bowel preparation for either anterior resection (12) or subtotal colectomy (1). Patients in the GDFT group received more colloid during surgery (mean 591 versus 297 ml; P = 0·012) and had superior cardiac indices (mean corrected flow time 374 versus 355 ms; P = 0·018). However, no differences were observed between the GDFT and fluid restriction groups with regard to surgical recovery (mean SRS after 7 days 47 versus 46 respectively; P = 0·853), other secondary outcomes (mean aldosterone/renin ratio 9 versus 8; P = 0·898), total postoperative fluid (median 3750 versus 2400 ml; P = 0·604), length of hospital stay (median 6 versus 5 days; P = 0·570) or number of patients with complications (26 versus 27; P = 1·000). GDFT did not provide clinical benefit in patients undergoing elective colectomy within a protocol incorporating fluid restriction. NCT00911391 (http://www.clinicaltrials.gov).

Product Number
Product Description

Sodium acetate, anhydrous, for molecular biology, ≥99%
Sodium acetate, anhydrous, ReagentPlus®, ≥99.0%
Sodium acetate trihydrate, ReagentPlus®, ≥99.0%
Sodium acetate, ACS reagent, ≥99.0%
Sodium acetate trihydrate, ACS reagent, ≥99%
Sodium acetate solution, BioUltra, for molecular biology, ~3 M in H2O
Sodium acetate, anhydrous, BioUltra, for luminescence, for molecular biology, ≥99.0% (NT)
Sodium acetate trihydrate, BioXtra, ≥99.0%
Sodium acetate, powder, BioReagent, suitable for electrophoresis, suitable for cell culture, suitable for insect cell culture, ≥99%
Sodium acetate trihydrate, meets USP testing specifications
Sodium acetate trihydrate, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, E262, 99.0-101.0% (calc. to the dried substance), ≤0.00002% Al
Sodium acetate, puriss. p.a., ACS reagent, reag. Ph. Eur., anhydrous
Sodium acetate, BioXtra, ≥99.0%
Sodium acetate trihydrate, BioUltra, ≥99.5% (NT)
Sodium acetate, meets USP testing specifications, anhydrous
Sodium acetate, 99.995% trace metals basis
Sodium acetate solution, NMR reference standard, 50 mM in D2O (99.9 atom % D), water 1 %, NMR tube size 3 mm × 8 in.

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.